England recorded more than 50,000 serious antibiotic-resistant infections in 2021, a 2.2% increase compared with 2020, the latest UK Health Security Agency (UKHSA) data shows.
However, the figure remained below pre-pandemic levels (62,422 in 2019), which the agency attributed to factors including changes in social mixing and enhanced hand hygiene during the pandemic.
The data also showed total antibiotic use fell by 15.1% in England between 2017 to 2021, from 18.8 Daily Defined Doses (DDD) per 1,000 inhabitants per day to 15.9.
Related Article: Mpox case reported in England with no travel or close contact history
This drop exceeded the government’s National Action Plan on antibiotic resistance target to reduce prescribing by 15% by 2024 compared with rates in 2014.
Recent estimates suggested that antimicrobial resistance caused 1.27 million deaths globally and 7,600 deaths in the UK each year.
UKHSA chief executive Professor Dame Jenny Harries said as the country emerged from the pandemic, this was a pivotal moment to ‘maintain focus on the ‘silent pandemic’ of antibiotic resistance through our extensive surveillance and antibiotic stewardship activities’.
While the number of severe antibiotic-resistant infections had reduced during the pandemic, resistance to some key antibiotics remained high, she added.
Over two-fifths of E. coli bloodstream infections were resistant to co-amoxiclav, a key antibiotic used in the treatment of serious infections in hospital, she said.
UKHSA had also identified resistance to a newer antibiotic cefiderocol in E. coli and Pseudomonas spp. bloodstream isolates in England.
Related Article: New government campaign to target AMR threat among young adults
Coinciding with the release of the latest data, the Government has launched a consultation to gather the latest evidence and data on antimicrobial resistance as part of its work to formulate its next five year action plan, which will run from 2024-29.
Dr Colin Brown, UKHSA deputy director of antimicrobial resistance and healthcare associated infections, said data and surveillance programmes had pinpointed several areas for actions, with targets to improve prescribing and limit antimicrobial-resistant and healthcare-associated infections over the last five years.
‘It is vital the future national action plan targets include measures to limit resistance, incentivise best practice in prescribing, and facilitate novel diagnostics and therapeutics,’ he said.
It was hoped the amnesty would remove antibiotics from circulation and prevent them from being disposed of unsafely – which could contaminate the environment and increase the spread of resistant genes among bacteria.
Related Article: Potential pathway for correcting penicillin allergy records
The antibiotic amnesty toolkit suggests that NHS organisations could work with community pharmacies, veterinary surgeries, and universities to collect unused antibiotics.
